

## INBJUDAN TILL BMS I-O WEBBFÖRELÄSNING

# Immunotherapy in adjuvant melanoma – overall survival, clinical experience and challenges in clinical praxis

**NU KAN DU ANMÄLA DIG** till denna webbföreläsning om immunterapi som adjuvant behandling av melanom. Under detta webinar kommer professor Olivier Michielin presentera överlevnadsdata och tillsammans med Gustav Ullenhag diskutera kliniska erfarenheter och utmaningar med adjuvant behandling vid malignt melanom.

Du har också möjlighet att få just dina frågor belysta i diskussionen genom att du kan ställa dem via chat under mötet.

Hoppas vi ses på nätet!

Med vänlig hälsning,

Alla vi på Bristol-Myers Squibb  
som arbetar med onkologisk immunterapi

**ANMÄL  
DIG HÄR!**

### TISDAG 20 OKTOBER 12.00 – 12.45 (ENG)

Immunotherapy in adjuvant melanoma – overall survival,  
clinical experience and challenges in clinical praxis.



#### FÖRELÄSARE

*Prof. Olivier Michielin, MD-PhD Head of Personalized Analytical Oncology, Head of Melanoma Clinic, Department of Oncology, Swiss Institute of Bioinformatics, Ludwig Institute, Lausanne, Switzerland*



#### MODERATOR

*Gustav Ullenhag, docent och överläkare, Onkolog-kliniken Akademiska Sjukhuset, Uppsala*

*Prof. Olivier Michielin obtained a Masters of Physics in 1991 at the Swiss Federal Institute of echnology and a Medical Degree from the University of Lausanne in 1997. He pursued his PhD training under the supervision of Jean-Charles Cerottini (Ludwig Institute) and Martin Karplus (Harvard and Strasbourg Universities, Chemistry Nobel Prize Laureate 2013). He was appointed Group Leader of the Swiss Institute of Bioinformatics in 2002 and became an Assistant Professor and Privat Docent at the Medical Faculty of Lausanne in 2004 and 2005, respectively. In parallel, he has trained as a medical oncologist and obtained his board certification in 2007 at the Oncology Department of Lausanne where he is currently heading the melanoma clinic. He was appointed Associate Professor in 2010 and full Professor in 2019. Prof. Olivier Michielin is mainly focused on translational oncology, developing new molecularly defined therapeutic approaches based on original bioinformatics techniques developed in his laboratory, as well as melanoma clinical trials at the Oncology Department. In 2016, Prof. Olivier Michielin has been appointed as the Head of Precision Oncology at the Lausanne University Hospital.*